
Gedatolisib
CAS No. 1197160-78-3
Gedatolisib ( PF-05212384 | PKI-587 )
产品货号. M10696 CAS No. 1197160-78-3
一种高效、选择性、双重 PI3K/mTOR 抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥365 | 有现货 |
![]() ![]() |
5MG | ¥583 | 有现货 |
![]() ![]() |
10MG | ¥988 | 有现货 |
![]() ![]() |
25MG | ¥1928 | 有现货 |
![]() ![]() |
50MG | ¥3621 | 有现货 |
![]() ![]() |
100MG | ¥5370 | 有现货 |
![]() ![]() |
500MG | ¥11259 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Gedatolisib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种高效、选择性、双重 PI3K/mTOR 抑制剂。
-
产品描述A highly potent, selective, dual PI3K/mTOR inhibitor with IC50 of 0.4/6/8/6/1.6 nM for PI3Kα/β/γ/δ/mTOR, respectively; also potently inhibits PI3Kα mutant H1047R and E545K with IC50 of 0.6 and 0.6 nM; prevents the pAkt at Thr 308 with IC50 of 8 nM, and suppresses pAkt S473 with IC50 of <10 nM in cells; demonstrates antitumor efficacy in both subcutaneous and orthotopic xenograft tumor models.Blood Cancer Phase 3 Clinical.
-
体外实验——
-
体内实验——
-
同义词PF-05212384 | PKI-587
-
通路PI3K/Akt/mTOR signaling
-
靶点PI3K
-
受体mTOR|PI3Kα|PI3Kγ
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1197160-78-3
-
分子量615.72
-
分子式C32H41N9O4
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(NC1=CC=C(C2=NC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=C1)NC5=CC=C(C(N6CCC(N(C)C)CC6)=O)C=C5
-
化学全称1-(4-{[4-(Dimethylamino)-1-piperidinyl]carbonyl}phenyl)-3-{4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}urea
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Venkatesan AM, et al. J Med Chem. 2010 Mar 25;53(6):2636-45.
2. Mallon R, et al. Clin Cancer Res. 2011 May 15;17(10):3193-203.
3. Gedaly R, et al. J Surg Res. 2013 Nov;185(1):225-30.
4. D'Amato V, et al. Br J Cancer. 2014 Jun 10;110(12):2887-95.